GLP-1 Ileus: Symptoms, Risk Factors, and Exactly When to Get Help

Quick triage: where do you fit right now?

What is GLP-1 ileus, exactly?

The plain-English version

Your intestines are a one-way conveyor belt. Food and waste move along it because the muscles in the bowel wall squeeze in coordinated waves — peristalsis. The underlying rhythm is called the migrating motor complex.

Ileus is what happens when the conveyor belt slows to a crawl or stops. Stuff doesn't move. Pressure builds. Fluid backs up. The belly swells. Vomiting starts. If it goes on long enough, the bowel can lose blood supply, which is the dangerous endgame nobody wants to reach.

GLP-1 medications — semaglutide, tirzepatide, liraglutide, dulaglutide, orforglipron — work in part by slowing this whole system down on purpose. That's why they reduce appetite. The food sits longer, you feel full longer, you eat less. Most people get away with this fine. A small minority slow down too much.

Ileus vs. ileum vs. bowel obstruction vs. gastroparesis

These get confused constantly. Worth pinning down:

How GLP-1 medications affect gut motility

Glucagon-like peptide-1 (GLP-1) is a hormone your gut already makes after meals. It tells your pancreas to release insulin, tells your brain you're full, and tells your stomach to empty more slowly. GLP-1 receptor agonists are drugs that mimic this hormone — at higher concentrations and for much longer than your body would naturally produce.

Slowed gastric emptying is on every GLP-1 label. It's not a bug; it's how the drugs work. The migrating motor complex in the small bowel is also affected — published research from Hellström and colleagues at the Karolinska Institute showed that GLP-1 inhibits the fasting-state contractions that sweep the small intestine clean between meals. (Hellström et al., Neurogastroenterology & Motility, 2008)

Stack that on top of dehydration, low fiber intake, opioids, anticholinergic medications, prior abdominal surgery, or pre-existing motility problems, and the math can occasionally tip into trouble.

Can GLP-1 medications cause ileus or bowel obstruction?

The FDA tracks adverse events that show up after a drug is approved through a system called FAERS — the FDA Adverse Event Reporting System. It's voluntary. Patients report what happened; clinicians report; manufacturers report. By mid-2023, FAERS had logged 33 reports of ileus from GLP-1 users with two reported deaths. (FDA FAERS data, via Fierce Pharma)

That signal triggered a label update. On September 20, 2023, the FDA required Novo Nordisk to add ileus to Ozempic's postmarketing experience section. (HCPLive coverage of FDA labeling change) Wegovy and Mounjaro already had similar language on their labels. By 2026, every major GLP-1 label includes ileus or intestinal obstruction language. The matrix below shows you exactly what each one says.

The label is what it is: a postmarketing safety signal from voluntary reports. The FDA itself cautions that these reports cannot reliably estimate frequency or establish causation. We'll cover what the actual research shows — and where it disagrees — in a section below.

When is GLP-1 ileus an emergency?

ER now: the red-flag cluster

Any of these on their own warrants urgent evaluation. Together, they're an emergency:

Same-day: call your prescriber or go to urgent care

Reach out today, not next week, if:

• ▸Constipation is worsening despite fluids, fiber, and OTC measures
• ▸New or persistent abdominal pain
• ▸More than one episode of vomiting
• ▸Trouble keeping fluids down
• ▸Severe GI symptoms after a recent dose increase
• ▸You have a history of bowel obstruction, severe gastroparesis, abdominal surgery, adhesions, hernia, or severe chronic constipation

Monitor at home — but don't ignore

Reasonable to wait and watch only if all of the following are true:

• ✓Mild constipation
• ✓Still passing gas
• ✓No vomiting
• ✓No severe pain
• ✓Able to hydrate
• ✓Trajectory is stable or improving

If you're constipated but the rest of the picture is calm, our GLP-1 constipation relief guide covers fiber timing, hydration, and the gentle laxative protocol most providers actually recommend.

What happens at the ER for possible ileus or bowel obstruction?

Knowing what to expect lowers the panic. A few things to internalize before you walk in:

• →

  The exam is fast. A trained ER clinician can usually tell within minutes whether your abdomen is a "watch carefully" abdomen or a "needs imaging right now" abdomen.

• →

  Imaging is targeted. They're not going to scan you for everything. They're going to look for the specific things ileus and obstruction show up as on the films.

• →

  Most cases get better with time and IV fluids. Bowel rest means no food or drink for a stretch (usually 24–48 hours), with IV fluids replacing what you're losing. The bowel often resumes normal function on its own once the offending input — in this case, possibly the GLP-1 — is paused.

• →

  Tell them you're on a GLP-1 immediately. It changes the differential and may change the imaging or sedation plan if they need to do a procedure.

Which GLP-1 drugs have ileus on the label? (FDA Label Evidence Matrix)

Verify each cell against the live label PDFs at accessdata.fda.gov before relying on it for medical decisions.

GLP-1 Ileus Label Evidence Matrix — verified April 30, 2026

Sources: DailyMed labels for each drug (cross-checked April 2026); FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.

What we searched: Each label for the exact strings “ileus,” “intestinal obstruction,” “severe constipation,” “fecal impaction,” “gastric emptying,” and “pulmonary aspiration.”

What “postmarketing” actually means

When a drug is approved, the clinical trials are over. Real-world use surfaces things trials never could — events too rare to show up in 5,000-person studies but real enough to matter when 10 million people take the drug.

Postmarketing experience sections are how those signals get on the label. The FDA's standard caveat — printed on every postmarketing section — is essentially this: we cannot reliably estimate frequency or establish causation from these reports. That doesn't mean the events are fake. It means the label is being honest about what it can and can't prove.

What this matrix does not mean

• ▸It does not mean every drug above has the same ileus risk. We don't have head-to-head incidence data.
• ▸It does not mean compounded versions have been FDA-reviewed. They haven't.
• ▸It does not mean you should stop your medication based on this page alone. That's a clinician decision unless symptoms are urgent.
• ▸It does not replace seeing a doctor when something feels wrong.

How common is GLP-1 ileus, really?

The four major studies side by side

Sources: Sodhi 2023 JAMA; Faillie 2022; Ueda 2024; Gao 2025 via NCBI PMC.

Why the studies disagree (and what to actually believe)

The Sodhi JAMA study had a small absolute number of obstruction events. The 95% confidence interval — 1.02 to 17.40 — tells you the precision was poor. A confidence interval that wide means the “true” effect could be anywhere from “barely above 1” to “17×.” Bupropion-naltrexone is also not a neutral reference drug; the comparison choice affects the relative risk calculation.

The Ueda Scandinavian study and the Gao 2025 TriNetX study compared GLP-1s to other diabetes drugs in much larger samples. In those comparisons, the relative risk shrinks to nothing or near nothing.

The honest synthesis: GLP-1s probably don't increase ileus risk much compared to similar diabetes drugs in similar patients. The relative-risk numbers from weight-loss-focused studies are imprecise and based on small event counts. The absolute rate is low across all of these — we're talking events that are rare enough that very large studies still struggle to count them precisely.

When the risk is highest

So if you're either currently in an escalation phase OR you've been on the drug for over a year, those are the two windows where extra vigilance makes the most sense.

A note on FAERS reports

As of September 2023, the FDA had received over 8,500 reports of GI disorders associated with semaglutide products, including 33 reports specifically of ileus from GLP-1 users and 2 reported deaths. That number has continued to accumulate.(FDA FAERS via Fierce Pharma)

The serious caveat: FAERS is voluntary reporting from a denominator of millions of users. Reports cannot establish causation, they undercount real events, and they don't tell you per-person risk. They're a signal, which is exactly what the FDA used them for to update the label.

How to tell normal GLP-1 constipation from possible ileus

Side-by-side: what's normal vs. what's concerning

Why “days since last bowel movement” alone isn't enough

People fixate on the BM count. It's the wrong number to fixate on alone.

A more reliable indicator is whether you can still pass gas. The intestines move gas before they move stool. If you're still passing gas, the bowel is still moving, even if it's slow. If you've stopped passing gas and stool and your belly is hard and getting more bloated and you're nauseated — that combination is the pattern that warrants urgent evaluation.

For mild constipation that doesn't fit the warning pattern, our GLP-1 constipation relief guide covers fiber timing, hydration math, and the gentle laxative protocol most providers actually recommend.

Who is most at risk for GLP-1 ileus?

Higher-caution history checklist

Each item raises baseline risk. The more that apply to you, the more important close monitoring and prescriber screening become:

The October 2024 ASA/AGA multi-society guidance specifically flags dose escalation, higher dose, weekly dosing, current GI symptoms, and conditions known to delay gastric emptying as the variables that move someone from “low-risk” to “elevated-risk” for GLP-1-related GI complications. These don't add up to a numeric score — they're risk factors a clinician weighs together.

Medication interactions that compound the risk

Several common medication classes slow gut motility on their own. Stacking them with a GLP-1 multiplies the effect:

• ▸Opioids (oxycodone, hydrocodone, tramadol, codeine) — even occasional use
• ▸Anticholinergics — diphenhydramine (Benadryl), oxybutynin, scopolamine, some tricyclic antidepressants
• ▸Iron supplements at high doses
• ▸Calcium-channel blockers (verapamil especially)
• ▸Aluminum-containing antacids
• ▸Some antiemetics — ironically, some of the drugs prescribed for GLP-1 nausea also slow the gut

If you take any of these regularly, mention them at every prescriber visit. A pharmacist consultation is genuinely worth the 10 minutes.

Five questions to ask before starting or escalating a GLP-1

A provider who can't answer these is a provider whose support infrastructure isn't built for the medication they're prescribing.

GLP-1s and surgery: the perioperative rules

Surgery is where GLP-1 problems most often go wrong. Postoperative ileus is already common — about 9% of patients develop it after even routine hysterectomy without any GLP-1 in the picture. (Cureus 2025 perioperative case report) Add a drug that delays gastric emptying and slows the small bowel, and the postoperative course gets more complicated.

The other risk surgery surfaces is pulmonary aspiration. If your stomach hasn't emptied before anesthesia, the contents can come up and into your lungs. That can be fatal. The current Ozempic DailyMed label notes pulmonary aspiration has occurred in GLP-1 receptor agonist patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.

What the October 2024 multi-society guidance actually says

Five major medical societies — ASA, AGA, ASMBS (bariatric surgery), ISPCOP (perioperative care of obese patients), and SAGES (gastrointestinal/endoscopic surgeons) — issued joint guidance on October 29, 2024. The headline: most patients can continue their GLP-1 before elective surgery.

The full guidance is on the ASA website and the AGA news page. If you're scheduling surgery, send your surgical team a link.

Endoscopy and colonoscopy

Same risk profile, slightly different concern. Retained gastric contents under sedation increase aspiration risk. The American Society for Gastrointestinal Endoscopy issued its own 2025 position statement — most platforms now ask about GLP-1 use in pre-procedure intake. Answer truthfully. If you've had your dose this week, say so.

Restarting after surgery

The lesson: do not restart your GLP-1 after surgery without explicit instructions from your surgical team. “Resume your normal medications” is not specific enough.

What to do if you think your GLP-1 caused ileus

What to tell the ER (copy-ready)

If you're heading to the emergency department, this is what you say at triage:

What to message your prescriber (copy-ready)

If you're not in immediate danger but you need a same-day or next-day touchpoint, send this through your portal:

What to bring to the ER or appointment

FDA MedWatch reporting

If a clinician confirms a serious adverse event tied to your GLP-1, ask whether the event should be reported through FDA MedWatch. You can submit your own report — it takes about 15 minutes. These reports are how postmarketing surveillance works. They're how the September 2023 label change happened in the first place. This is not the same as filing a lawsuit.

Should you stop your GLP-1 after a possible ileus?

The typical clinical course

In the published case literature, the pattern is reassuring: GLP-1 is held, conservative treatment (NPO, IV fluids, sometimes nasogastric decompression) is started, and within days the bowel function returns. (AJG 2024 case report); (Cureus 2025 case report)

The dangerous progression is when ileus tips into bowel ischemia — loss of blood supply to the gut. That requires emergency surgery. It's rare in the published reports, but it's the reason “let me ride this out at home” is a bad strategy when the warning signs are present.

Questions to ask before restarting

If you've had an ileus episode (or a near-miss that involved an ER visit, imaging, or holding doses), don't restart on autopilot. Take this list to your prescriber and a GI specialist:

1. 1

   Was ileus, obstruction, fecal impaction, or gastroparesis confirmed by imaging or other testing?

2. 2

   Did you think the GLP-1 contributed, or was something else more likely?

3. 3

   Was there a dose increase right before symptoms started?

4. 4

   Should I restart at a lower dose, slow the titration, switch medications, or stop?

5. 5

   What constipation prevention plan should I follow if I restart?

6. 6

   Which symptoms mean I should not take the next dose?

7. 7

   Who do I call after hours if symptoms return?

8. 8

   Should I see a gastroenterologist before restarting?

This is also a fair moment to evaluate whether your current provider is the right level of support. A provider who says “just take it again, you'll probably be fine” after a bowel-related ER visit is not a provider with the medical depth this medication requires.

Does compounded semaglutide or tirzepatide change the picture?

What FDA actually says about compounded GLP-1s

The FDA's own Concerns with Unapproved GLP-1 Drugs Used for Weight Loss page lays it out directly:

• ▸Compounded versions are not FDA-approved.
• ▸The FDA does not review them for safety, effectiveness, or quality before marketing.
• ▸The FDA has received adverse-event reports tied to compounded versions, including dosing errors that resulted in hospitalization. As of July 31, 2025, FDA had received 605 reports involving compounded semaglutide and 545 involving compounded tirzepatide.
• ▸Adverse events with compounded products are likely underreported because federal law does not require state-licensed compounding pharmacies that are not outsourcing facilities to submit adverse-event reports to FDA.
• ▸Some compounded products use unapproved salt forms of semaglutide that are not the same molecule as FDA-approved Ozempic or Wegovy.
• ▸Storage, shipping, and labeling vary by source.

What to verify if you're using a compounded GLP-1

The biggest practical failure mode in compounded GLP-1 programs is the support gap. Medication arrives on schedule; clinical guidance is thin; when something goes wrong, the patient doesn't know who to call.

If safety is your priority: a note on FDA-approved options

This is the only commercial routing block on this page. We held it until now on purpose. If you're not in the higher-risk category and you're happy with your current program, ignore this section — it's not for you.

When FDA-approved is genuinely the better path

Two practical advantages:

If you're low-risk, healthy, on a stable dose, and your current provider answers messages within hours, you're probably fine where you are. Don't switch for the sake of switching.

Insurance coverage and prior authorization: where to actually start

This is the only specific provider we're going to name on this page, because it's the only one we believe fits the specific reader who got this far on a safety page.

The damaging admission: Ro is not the cheapest option. Ongoing membership at standard pricing is $149/month — meaningfully more than the cheapest compounded programs — and your medication cost is on top of that. If your priority is the absolute lowest cash-pay cost and you're low-risk, our GLP-1 matching quiz and our best FDA-approved GLP-1 providers comparison route to better-fit options. But if you're a higher-risk reader who reached the end of a safety page, the insurance route is usually the right starting point — and Ro is the cleanest insurance route in the FDA-approved lane.

GLP-1 Ileus FAQ

Related guides on Weight Loss Provider Guide

• GLP-1 side effects: normal vs. ER-worthy — the broader triage hub
• GLP-1 constipation relief that actually works — for mild constipation without red flags
• GLP-1 matching quiz — for readers who want a personalized provider recommendation
• Compare FDA-approved GLP-1 provider options — for readers who want the insurance / approved medication path